Form 4: Theravance Biopharma Executive Sells 4,000 Shares Under 10b5-1 Plan

Rhonda Farnum, SVP at Theravance Biopharma, sold 4,000 ordinary shares at $9 each, according to a recent SEC filing.

Summary

• Rhonda Farnum, a Senior Vice President at Theravance Biopharma, sold 4,000 ordinary shares of the company.
• The sale occurred on November 11, 2024, at a price of $9 per share.
• This transaction was executed under a pre-arranged 10b5-1 trading plan established on March 14, 2024.
• Following the sale, Ms. Farnum still beneficially owns 322,743 ordinary shares.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing of an insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine disclosure of an insider transaction, which is common for publicly traded companies. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any recent material non-public information.

Comparison to Industry Standards

• Executive stock sales are a common occurrence in publicly traded companies, particularly those in the biotechnology sector like Theravance Biopharma.
• The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading, aligning with industry best practices.
• Similar transactions are regularly reported by executives at comparable companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but the pre-planned nature of the sale mitigates any significant concern.

Key Dates

Keywords

Theravance Biopharma, insider trading, SEC Form 4, stock sale, 10b5-1 plan, executive transaction, TBPH